Jenscare Scientific Shows Promising Growth in Interim Results
Jenscare Scientific Reports Significant Interim Results
Jenscare Scientific Co., Ltd. (HKEX: 9877), a pioneering medical device firm specializing in interventional treatments for structural heart diseases, recently showcased its interim results for the first half of 2025, marking a significant step forward in its product development and commercialization efforts.
Business Milestones: Advancements in Heart Disease Solutions
Throughout the period, Jenscare achieved notable milestones in several key product lines:
LuX-Valve Series and TTVR System
The multicenter clinical trial for the LuX-Valve series in China has transitioned into the long-term follow-up phase, yielding positive results. Additionally, a significant Randomized Controlled Trial (RCT) concerning optimized medical therapy has completed participant enrollment. The registration application for this innovative valve system has been accepted by authorities, now progressing through the regulatory registration stage.
European Progress with LuX-Valve Plus
In Europe, the LuX-Valve Plus's TRINITY clinical trial has completed its 6-month follow-up, which is a pivotal phase for acquiring CE Marking, and is currently under evaluation for registration.
Advancements in the U.S. Market
The IDE Early Feasibility Study of the LuX-Valve Plus in the United States has also concluded its subject enrollment. On a positive note, reimbursement for the device and associated costs has been secured from CMS, paving the way for the next steps toward approval and initiation of the pivotal study.
Ken-Valve System: Expanding Market Presence
The Ken-Valve, which recently received approval from regulatory bodies, is gaining traction in the market. Jenscare is actively pursuing commercialization, with hospitals beginning to adopt this innovative valve designed primarily to address aortic regurgitation and other related conditions, meeting substantial clinical needs.
JensClip: Global Expansion Efforts
For the JensClip, the registration application has been submitted and is now in the registration phase. The globalization of JensClip is underway, with successful pre-commercialization implantations taking place in international markets, showcasing promising outcomes. Efforts for CE Marking are actively being pursued to facilitate European market entry.
Financial Highlights: Strong Growth in Revenue
On the financial front, Jenscare reported total revenue of US$ 3.6 million for the first half of 2025, indicating robust growth. Gross profit and sales profit were reported at US$ 1.7 million and US$ 1.1 million respectively, yielding gross and sales profit margins close to 90% and 60%. Despite an adjusted non-IFRS loss of US$ 12.9 million, there was a decrease of about 3% compared to the same period last year, indicating operational efficiency.
The net loss per share attributed to ordinary shareholders, both basic and diluted, was US$ 0.06. Moreover, cash reserves, including cash and equivalents, totaled US$ 84.6 million. Notably, the net cash used in operating activities was US$ 13 million, reflecting a decrease of approximately 15% compared to the prior year.
Jenscare’s Commitment to Heart Health Solutions
As Jenscare continues to advance its commitment to innovative solutions for heart health, its ongoing developments highlight the company's focus on meeting urgent medical needs through pioneering heart valve technology. The collaborative efforts in clinical research and regulatory engagement display Jenscare's strategic positioning for future growth in the competitive medical device market.
Frequently Asked Questions
What is Jenscare Scientific known for?
Jenscare is a medical device company specializing in interventional treatments for structural heart diseases.
What products has Jenscare been developing?
Jenscare has been developing the LuX-Valve series, the Ken-Valve, and JensClip for treating various heart conditions.
What are the recent financial results for Jenscare?
Jenscare reported a total revenue of US$ 3.6 million with strong profit margins, despite a modest increase in losses.
How is Jenscare expanding internationally?
Jenscare is actively pursuing regulatory approvals in Europe and the U.S. for its product offerings, including submissions for CE Marking.
What is the significance of the LuX-Valve system?
The LuX-Valve system is essential for treating structural heart diseases, showing promising results in both clinical and regulatory evaluations.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.